A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $160 to $207

Moomoo NewsNov 22 08:00 ET · Ratings

Jazz Pharmaceuticals Insiders Sold US$1.7m Of Shares Suggesting Hesitancy

Simply Wall StNov 22 05:59 ET

Barclays Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

TipRanksNov 22 05:27 ET · Ratings

FDA Roundup: November 22, 2024

US FDANov 21 19:00 ET

Jazz Pharmaceuticals: Promising Growth Potential With Robust Pipeline and Undervalued Market Position

TipRanksNov 21 12:25 ET

Express News | FDA Grants Accelerated Approval to Zanidatamab-Hrii for Previously Treated Unresectable or Metastatic Her2-Positive Biliary Tract Cancer

ReutersNov 21 11:22 ET